Changes in Cytokine Levels in Patients with Severe Fever with Thrombocytopenia Syndrome Virus

References

• Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364(16):1523–1532. doi:10.1056/NEJMoa1010095
   PubMed Web of Science ®Google Scholar
• Zhan J, Wang Q, Cheng J, et al. Current status of severe fever with thrombocytopenia syndrome in China. Virol Sin. 2017;32(1):51–62. doi:10.1007/s12250-016-3931-1
   PubMed Web of Science ®Google Scholar
• Kim KH, Yi J, Kim G, et al. Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis. 2013;19(11):1892–1894. doi:10.3201/eid1911.130792
   PubMed Web of Science ®Google Scholar
• Takahashi T, Maeda K, Suzuki T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis. 2014;209(6):816–827. doi:10.1093/infdis/jit603
   PubMed Web of Science ®Google Scholar
• Tran XC, Yun Y, Van An L, et al. Endemic severe fever with thrombocytopenia syndrome, Vietnam. Emerg Infect Dis. 2019;25(5):1029–1031. doi:10.3201/eid2505.181463
   PubMed Web of Science ®Google Scholar
• Win AM, Nguyen YTH, Kim Y, et al. Genotypic heterogeneity of Orientia tsutsugamushi in scrub typhus patients and thrombocytopenia syndrome co-infection, Myanmar. Emerg Infect Dis. 2020;26(8):1878–1881. doi:10.3201/eid2608.200135
   PubMed Web of Science ®Google Scholar
• Mendoza CA, Ebihara H, Yamaoka S. Immune modulation and immune-mediated pathogenesis of emerging tickborne Banyangviruses. Vaccines (Basel). 2019;7(4). doi:10.3390/vaccines7040125
   PubMed Web of Science ®Google Scholar
• Zhou CM, Qi R, Qin XR, et al. Oral and ocular transmission of severe fever with thrombocytopenia syndrome virus. Infect Med. 2022;1(1):2–6. doi:10.1016/j.imj.2021.12.002
   Google Scholar
• Wang M, Tan W, Li J, Fang L, Yue M. The endless wars: severe fever with thrombocytopenia syndrome virus, host immune and genetic factors. Front Cell Infect Microbiol. 2022;12:808098. doi:10.3389/fcimb.2022.808098
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10. doi:10.1038/cmi.2015.74
   PubMed Web of Science ®Google Scholar
• Jarczak D, Nierhaus A. Cytokine storm-definition, causes, and implications. Int J Mol Sci. 2022;23(19). doi:10.3390/ijms231911740
   PubMed Web of Science ®Google Scholar
• Hu LF, Wu T, Wang B, et al. The regulation of seventeen inflammatory mediators are associated with patient outcomes in severe fever with thrombocytopenia syndrome. Sci Rep. 2018;8(1):159. doi:10.1038/s41598-017-18616-z
   PubMedGoogle Scholar
• He Z, Wang B, Li Y, et al. Changes in peripheral blood cytokines in patients with severe fever with thrombocytopenia syndrome. J Med Virol. 2021;93(8):4704–4713. doi:10.1002/jmv.26877
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin C, Zhan F, et al. Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. J Infect Dis. 2012;206(7):1085–1094. doi:10.1093/infdis/jis452
   PubMed Web of Science ®Google Scholar
• Liu MM, Lei XY, Yu H, Zhang JZ, Yu XJ. Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome. Virol J. 2017;14(1):6. doi:10.1186/s12985-016-0677-1
   PubMedGoogle Scholar
• Ministry of Health of the People’s Republic of China. National guideline for prevention and control of severe fever with thrombocytopenia syndrome (2010 edition). Chin J Clin Infect Dis. 2011;4:1.
   Google Scholar
• Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–2273. doi:10.1056/NEJMra2026131
   PubMed Web of Science ®Google Scholar
• Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185–194. doi:10.1002/jmv.20255
   PubMed Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. doi:10.1126/science.abb8925
   PubMed Web of Science ®Google Scholar
• Cao XT. Medical Immunology. 7th ed. China: People’s Medical Publishing House; 2018.
   Google Scholar
• Guo J, Guo X, Wang Y, Tian F, Luo W, Zou Y. Cytokine response to Hantaan virus infection in patients with hemorrhagic fever with renal syndrome. J Med Virol. 2017;89(7):1139–1145. doi:10.1002/jmv.24752
   PubMed Web of Science ®Google Scholar
• Jansen van Vuren P, Shalekoff S, Grobbelaar AA, et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease. Virol J. 2015;12:159. doi:10.1186/s12985-015-0392-3
   PubMed Web of Science ®Google Scholar
• Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003;10(3–4):335–350. doi:10.1038/sj.mn.7800198
   PubMed Web of Science ®Google Scholar
• Sowa Y, Kishida T, Tomita K, Adachi T, Numajiri T, Mazda O. Involvement of PDGF-BB and IGF-1 in activation of human Schwann cells by platelet-rich plasma. Plast Reconstr Surg. 2019;144(6):1025e–1036e. doi:10.1097/PRS.0000000000006266
   PubMed Web of Science ®Google Scholar
• Coppola C, Hopkins B, Huhn S, Du Z, Huang Z, Kelly WJ. Investigation of the Impact from IL-2, IL-7, and IL-15 on the growth and signaling of activated CD4(+) T cells. Int J Mol Sci. 2020;21(21):7814. doi:10.3390/ijms21217814
   PubMed Web of Science ®Google Scholar
• Li MM, Zhang WJ, Weng XF, et al. CD4 T cell loss and Th2 and Th17 bias are associated with the severity of severe fever with thrombocytopenia syndrome (SFTS). Clin Immunol. 2018;195:8–17. doi:10.1016/j.clim.2018.07.009
   PubMed Web of Science ®Google Scholar
• Cui N, Liu R, Lu QB, et al. Severe fever with thrombocytopenia syndrome bunyavirus-related human encephalitis. J Infect. 2015;70(1):52–59. doi:10.1016/j.jinf.2014.08.001
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–189. doi:10.1189/jlb.0603252
   PubMed Web of Science ®Google Scholar
• Zhang YZ, He YW, Dai YA, et al. Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome. Clin Infect Dis. 2012;54(4):527–533. doi:10.1093/cid/cir804
   PubMed Web of Science ®Google Scholar
• Ding YP, Liang MF, Ye JB, et al. Prognostic value of clinical and immunological markers in acute phase of SFTS virus infection. Clin Microbiol Infect. 2014;20(11):O870–O878. doi:10.1111/1469-0691.12636
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spano F, Contatore M, et al. Infection risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf. 2015;14(4):571–582. doi:10.1517/14740338.2015.1009036
   PubMed Web of Science ®Google Scholar
• Chen H, Hu K, Zou J, Xiao J. A cluster of cases of human-to-human transmission caused by severe fever with thrombocytopenia syndrome bunyavirus. Int J Infect Dis. 2013;17(3):e206–208. doi:10.1016/j.ijid.2012.11.006
   PubMed Web of Science ®Google Scholar
• Cui N, Bao XL, Yang ZD, et al. Clinical progression and predictors of death in patients with severe fever with thrombocytopenia syndrome in China. J Clin Virol. 2014;59(1):12–17. doi:10.1016/j.jcv.2013.10.024
   PubMed Web of Science ®Google Scholar
• Wu J, Huang GT, He W, et al. Basic fibroblast growth factor enhances stemness of human stem cells from the apical papilla. J Endod. 2012;38(5):614–622. doi:10.1016/j.joen.2012.01.014
   PubMed Web of Science ®Google Scholar
• Li MM, Zhang WJ, Liu J, et al. Dynamic changes in the immunological characteristics of T lymphocytes in surviving patients with severe fever with thrombocytopenia syndrome (SFTS). Int J Infect Dis. 2018;70:72–80. doi:10.1016/j.ijid.2018.03.010
   PubMed Web of Science ®Google Scholar
• Li M, Xiong Y, Li M, et al. Depletion but activation of CD56(dim)CD16(+) NK Cells in acute infection with severe fever with thrombocytopenia syndrome virus. Virol Sin. 2020;35(5):588–598. doi:10.1007/s12250-020-00224-3
   PubMed Web of Science ®Google Scholar
• Hu L, Kong Q, Yue C, He L, Xia L, Li J. Differences in immune damage between patients with severe fever with thrombocytopenia syndrome and patients with tsutsugamushi disease. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(8):947–952. doi:10.3760/cma.j.cn121430-20200420-00314
   PubMedGoogle Scholar
• Basler CF. Molecular pathogenesis of viral hemorrhagic fever. Semin Immunopathol. 2017;39(5):551–561. doi:10.1007/s00281-017-0637-x
   PubMed Web of Science ®Google Scholar
• Deng B, Zhang S, Geng Y, et al. Cytokine and chemokine levels in patients with severe fever with thrombocytopenia syndrome virus. PLoS One. 2012;7(7):e41365. doi:10.1371/journal.pone.0041365
   PubMed Web of Science ®Google Scholar
• Dorner BG, Scheffold A, Rolph MS, et al. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A. 2002;99(9):6181–6186. doi:10.1073/pnas.092141999
   PubMed Web of Science ®Google Scholar
• Melik-Parsadaniantz S, Rostene W. Chemokines and neuromodulation. J Neuroimmunol. 2008;198(1–2):62–68. doi:10.1016/j.jneuroim.2008.04.022
   PubMed Web of Science ®Google Scholar
• Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity. 2008;28(4):468–476. doi:10.1016/j.immuni.2008.03.003
   PubMed Web of Science ®Google Scholar
• Yoo JR, Kim TJ, Heo ST, et al. IL-6 and IL-10 Levels, Rather Than Viral Load and Neutralizing Antibody Titers, Determine the Fate of Patients With Severe Fever With Thrombocytopenia Syndrome Virus Infection in South Korea. Front Immunol. 2021;12:711847. doi:10.3389/fimmu.2021.711847
   PubMed Web of Science ®Google Scholar
• Kang SY, Yoo JR, Park Y, et al. Fatal outcome of severe fever with thrombocytopenia syndrome (SFTS) and severe and critical COVID-19 is associated with the hyperproduction of IL-10 and IL-6 and the low production of TGF-β. J Med Virol. 2023;95(7):e28894. doi:10.1002/jmv.28894
   PubMed Web of Science ®Google Scholar
• Xia Y, Frangogiannis NG. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets. 2007;6(2):101–107. doi:10.2174/187152807780832265
   PubMedGoogle Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. doi:10.1089/jir.2008.0027
   PubMed Web of Science ®Google Scholar